First off, the great news. My son’s condition apparently is not as bad as first feared: it is not likely his condition has turned malignant, according to the most NF2 knowledgeable in the field. Dealing with a rare condition is often a lesson in learning how much people of high specialty don’t know, as is seems to be in this case.
Specifically, they performed a test (PET CT Scan, which measures the uptake of radioactively tagged glucose) that is rarely done on NF2 patients and spoke with a level of assurance not warranted on the meaning of the result. Had we not been the types to do ‘due diligence’, as one doctor put it, we would have gone with the opinion of the first two doctors (the radiologist and neurooncologist) and had Alan scheduled for surgery that would cause permanent debilitation of his right leg. Even the severity of that debilitation is an issue: one doctor said it would be mild, while two said it was dependant on nerve dominance, with one fairly sure that leg bracing will be required. These last two doctors expressed more concern about Alan’s other tumors that the one in the leg; one more concerned about the slow growth of the acoustical neuroma that affects his left hearing, the other a small ependinoma in the spinal cord.